The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

GlaxoSmithKline PLC

NYSE: GSK
Last

(U.S.) $43.35

Today's change0.00 0.00%
Updated December 19 4:03 PM EST. Delayed by at least 15 minutes.
 

GlaxoSmithKline PLC

NYSE: GSK
Last

(U.S.) $43.35

Today's change0.00 0.00%
Updated December 19 4:03 PM EST. Delayed by at least 15 minutes.

GlaxoSmithKline PLC closed at (U.S.)$43.35.

Over the last five days, shares have gained 2.19%, but sit 4.99% above the 52-week low. Shares have underperformed the S&P 500 by 30.37% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $43.35
  • High--
  • Low--
  • Bid / Ask(U.S.) $43.80 / (U.S.) $43.83
  • YTD % change-18.81%
  • Volume23,750
  • Average volume (10-day)5,863,129
  • Average volume (1-month)4,099,435
  • Average volume (3-month)5,050,922
  • 52-week range(U.S.) $41.29 to (U.S.) $56.73
  • Beta0.65
  • Trailing P/E16.16×
  • P/E 1 year forward14.34×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $2.65
  • Dividend yield6.12%
  • Trailing EPS(U.S.) $2.68
Updated December 19 4:03 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.17%

Based on its net profit margin of 18.17%, GlaxoSmithKline PLC is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue5,6465,5615,6136,906
Total other revenue--------
Total revenue5,6465,5615,6136,906
Gross profit3,8943,8883,9084,773
Total cost of revenue1,7521,6731,7052,133
Total operating expense4,9434,4244,5474,212
Selling / general / administrative1,7951,9691,9192,094
Research & development742766784905
Depreciation / amortization17172323
Interest expense (income), net operating--------
Unusual expense (income)73871186-845
Other operating expenses, total-101-72-70-98
Operating income7031,1371,0662,694
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax5489869032,546
Income after tax3857027192,505
Income tax, total16328418441
Net income4016546682,461
Total adjustments to net income--------
Net income before extra. items4016546682,461
Minority interest16-48-51-44
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items4016546682,461
Inc. avail. to common incl. extra. items4016546682,461
Diluted net income4016546682,461
Dilution adjustment------0
Diluted weighted average shares4,8654,8744,8664,881
Diluted EPS excluding extraordinary itemsvalue per share0.080.130.140.50
Dividends per sharevalue per share0.190.190.190.23
Diluted normalized EPSvalue per share0.210.160.170.25